by Denkstrom
All storiesFalling Walls honours Erlangen CAR-T researcher Schett

Falling Walls honours Erlangen CAR-T researcher Schett

On September 9, 2026, the Falling Walls Foundation named Georg Schett, the lead CASTLE investigator at FAU Erlangen-Nürnberg, the Science Breakthrough of the Year 2026 winner in the Life Sciences category for his work “Breaking the Wall of Autoimmune Diseases”. According to the foundation, the approach is intended to reset the immune system and enable long-lasting remission without ongoing medication, and was investigated in the small, non-randomised CASTLE study without a control group. The winners were selected from 2000 submissions from 474 academic institutions worldwide.

According to the organisers, the Falling Walls Science Summit 2026 was scheduled for November 6 to 9 at the Falling Walls Science House in Berlin. Schett and the other honourees were due to present their work live on stage there on the final day of the summit, as the foundation had announced in September.

How the approach is intended to reset the immune system

According to the foundation's announcement, Schett developed an approach aimed at a cure in which the body's own T cells are used to produce so-called living medicines. By adapting a cell therapy originally developed against cancer, he showed that CD19 CAR-T cells can remove the immune cells that drive autoimmune diseases. Schett himself said the strategy went beyond merely controlling symptoms and targeted the underlying cause.

What the CASTLE study shows

The CASTLE study, a phase 1/2a basket study described by Müller and colleagues in the journal Nature Medicine, tested the CD19 CAR-T cell product zorpocabtagene autoleucel, or Zorpo-cel, in treatment-resistant systemic lupus erythematosus, systemic sclerosis and idiopathic inflammatory myopathies. According to the trial registry, CASTLE is designed as an open-label study. Zorpo-cel is an autologous T-cell product modified using a lentiviral vector to produce a CAR targeting the B-cell antigen CD19. 28 people were screened for the study, and 24 were ultimately enrolled. The others were excluded because of infections or severely impaired lung function. Before treatment, participants had undergone a median of four unsuccessful immunosuppressive treatments; after these were discontinued and following lymphodepletion with cyclophosphamide and fludarabine, each patient received a single Zorpo-cel infusion.

After 24 weeks, 22 of 24 patients met the predefined efficacy targets. In systemic lupus, 9 of 10 patients achieved DORIS remission. In systemic sclerosis, 9 of 9 patients showed no progression of interstitial lung disease, while in myopathies, 4 of 5 patients achieved a major or moderate response according to ACR criteria. All patients remained off glucocorticoids and without further immunosuppressive treatment throughout the 24 weeks. As adverse effects, 17 of 24 patients developed grade 1 cytokine release syndrome, and one patient with systemic sclerosis developed grade 2; no higher grade or CAR-T-associated neurotoxicity (ICANS) occurred. 14 patients therefore received at least one dose of tocilizumab, and four received dexamethasone. Among the 13 patients who had B cells at baseline and showed sufficient B-cell recovery, naive B cells subsequently accounted for more than 90 percent, while memory cells and plasmablasts almost disappeared; in four of the 24 patients, B cells did not return at all within six months. Müller and colleagues view CASTLE as an indication of the feasibility, safety and efficacy of Zorpo-cel in three different autoimmune diseases and as paving the way for a registrational study.

Open questions and warnings from experts

The ClinicalTrials.gov trial registry most recently listed May 31, 2026, as the estimated completion date, but the entry had already been updated on September 30, 2025, with Schett as principal investigator and Miltenyi Biomedicine GmbH as the industry sponsor. The expert Ina Kötter, quoted in the press release from the German Society for Rheumatology and Clinical Immunology (DGRh), stressed that a possible “immune reset”, in which immune cells important to the disease are removed and the immune system is reorganised, was scientifically different from evidence of a permanent cure. A review dated November 6, 2026 reaches a similar conclusion and warns that such an immune reset must not be equated with a cure. A retrospective cohort of 108 CAR-T-treated autoimmune patients from six German centres and one Chinese centre, published in Lancet Rheumatology, recorded mostly mild cytokine release syndrome in 86 of them and ICANS in three. A systematic review of 115 autoimmune patients reported similar figures in September 2026, yet described its own findings as preliminary. The Paul-Ehrlich-Institut had stated as early as December 2025 that the EMA's pharmacovigilance committee considered secondary tumours following CAR-T treatment possible, although this concerned the oncology uses approved to date. Nevertheless, the committee maintained a positive benefit-risk assessment. An international panel of experts from EBMT, ISCT and JACIE published initial practice recommendations as early as 2024 and updated them with the version published on October 5, 2026; it describes CAR-T cells as a promising option emerging since 2021 for severe, treatment-resistant autoimmune diseases, but continues to identify unmet needs and open research questions.